Cellmid Limited’s (ASX:CDY) directors have demonstrated their support for the company by participating in a recent share placement.
Following the approval of shareholders at a general meeting held on November 19, chief executive officer Maria Halasz acquired 600,000 fully paid ordinary shares at 20 cents per share with a value of $120,000.
Non-executive director Dennis Eck acquired 2.5 million shares at 20 cents per share for a value of $500,000 and a further 217,391 shares at 23 cents per share.
Eck increased his substantial holding to 8,178,970 shares, which represents an 8.47% stake in the company.
Directors participate in SPP
Earlier this month chairman David King and non-executive directors Bruce Gordon and Dr Martin Cross participated in a share purchase plan (SPP) which closed on October 14 after raising $1.044 million.
The SPP exceeded the original $500,000 target by the board.
King acquired 300,000 fully paid ordinary shares valued at $60,000, Bruce Gordon acquired 50,000 shares valued at $10,000 and Cross acquired 150,000 shares valued at $30,000.
Cellmid also recently entered into a national trading agreement with API Services Australia Pty Ltd (API) for the ranging of its évolis® professional anti-ageing haircare products in 400 Priceline pharmacy stores around Australia.
The agreement is expected to deliver exclusive offers and unique hair advisory services to Priceline pharmacy customers.